The Vanguard Group has filed an amended Schedule 13G/A with the Securities and Exchange Commission on November 13, 2024, indicating a change in their holdings of bluebird bio, Inc. common stock. As of September 30, 2024, The Vanguard Group reported beneficial ownership of 10,474,007 shares of bluebird bio, which represents 5.40% of the company's class of common stock. The filing shows that The Vanguard Group has shared voting power over 87,543 shares and sole dispositive power over 10,330,825 shares, with an additional shared dispositive power over 143,182 shares. The Vanguard Group, a Pennsylvania-based investment adviser, stated that the securities were not acquired for the purpose of changing or influencing the control of bluebird bio, Inc. and were not held in connection with any transaction having that purpose or effect.

The Vanguard Group has filed an amended Schedule 13G/A with the Securities and Exchange Commission on November 13, 2024, indicating a change in their holdings of bluebird bio, Inc. common stock. As of September 30, 2024, The Vanguard Group reported beneficial ownership of 10,474,007 shares of bluebird bio, which represents 5.40% of the company's class of common stock. The filing shows that The Vanguard Group has shared voting power over 87,543 shares and sole dispositive power over 10,330,825 shares, with an additional shared dispositive power over 143,182 shares. The Vanguard Group, a Pennsylvania-based investment adviser, stated that the securities were not acquired for the purpose of changing or influencing the control of bluebird bio, Inc. and were not held in connection with any transaction having that purpose or effect.